The company has announced positive data from the ACHIEVE-2 and ACHIEVE-5 trials, with both meeting all their primary and key ...
Results obtained by Gilead and Arcus could rekindle interest in the anti-TIGIT modality, which has seen many setbacks in the ...
Johnson & Johnson’s targeted therapeutic combination, Tecvayli-Darzalex Faspro, performed better than investigator’s choice standard of care in a Phase III trial recruiting patients with R/R multiple ...
dashClinical provides instant payments that enhance trial completion and subject retention. Credit: PeopleImages/Shutterstock.com. Dash Solutions has introduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback